aTyr Pharma, Inc. (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Analysts

aTyr Pharma, Inc. (NASDAQ:ATYR - Get Free Report) has been given a consensus recommendation of "Buy" by the seven ratings firms that are presently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $20.20.

A number of brokerages have issued reports on ATYR. HC Wainwright reissued a "buy" rating and issued a $35.00 price target on shares of aTyr Pharma in a report on Wednesday, June 4th. Wells Fargo & Company boosted their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a research report on Friday, June 20th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Federated Hermes Inc. acquired a new position in aTyr Pharma during the fourth quarter worth $53,093,000. Point72 Asset Management L.P. acquired a new position in aTyr Pharma during the fourth quarter worth $17,677,000. Octagon Capital Advisors LP raised its holdings in aTyr Pharma by 294.7% during the first quarter. Octagon Capital Advisors LP now owns 3,552,000 shares of the company's stock worth $10,727,000 after purchasing an additional 2,652,000 shares during the last quarter. Tikvah Management LLC acquired a new position in shares of aTyr Pharma in the fourth quarter worth $8,908,000. Finally, Woodline Partners LP acquired a new position in shares of aTyr Pharma in the fourth quarter worth $6,092,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

aTyr Pharma Stock Performance

Shares of aTyr Pharma stock opened at $5.79 on Friday. The firm has a market cap of $515.31 million, a P/E ratio of -7.15 and a beta of 0.89. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 12 month low of $1.58 and a 12 month high of $5.98. The stock's fifty day moving average price is $4.76 and its 200-day moving average price is $3.92.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. On average, equities research analysts expect that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.